Share

UCB SA (UCB.BRU) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+70.9%

Includes 0.80% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is straightforward: UCB's operating performance is accelerating while its share price has fallen 28% from February's peak. The evidence points to a discount-rate and policy-uncertainty de-rating, not an earnings problem — guidance was raised twice in 2026 and H1 EBITDA margin reached 40.7% [1][4]. Over five years BIMZELX should carry group revenue from roughly €8.5bn trailing toward €13-14bn as legacy erosion annualises out, while US net-price compression and tariffs skim several points off realised margin. Investors are paid roughly 18x for mid-teens earnings growth with no loss of exclusivity until 2033. That is a reasonable, not spectacular, bargain.

Trailing near €11.6 reconstructed from semi-annual reporting; mid-teens growth implies €19-21 by 2031.
At a 16-17x exit multiple that supports roughly €330-350 per share, versus €208 today.
Cross-check: implied 2031 equity value near €65bn on €13-14bn revenue — undemanding for a 40% EBITDA-margin franchise.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (EUR)
Observed price	2021-09-15	91.9
Observed price	2021-10-05	98.1
Observed price	2021-10-13	97.8
Observed price	2021-10-29	103
Observed price	2021-11-10	106
Observed price	2021-11-22	98.4
Observed price	2021-11-26	99.6
Observed price	2021-11-30	96.8
Observed price	2021-12-28	100
Observed price	2022-01-09	93.9
Observed price	2022-01-13	90.6
Observed price	2022-01-25	86.8
Observed price	2022-02-14	86.1
Observed price	2022-02-26	96.6
Observed price	2022-03-06	96.7
Observed price	2022-03-22	105
Observed price	2022-03-26	107
Observed price	2022-04-15	115
Observed price	2022-04-19	112
Observed price	2022-05-09	100
Observed price	2022-05-13	98.6
Observed price	2022-06-02	81.6
Observed price	2022-06-10	82.3
Observed price	2022-06-18	78.9
Observed price	2022-06-30	82.4
Observed price	2022-07-12	85.6
Observed price	2022-07-24	79.5
Observed price	2022-08-13	73.2
Observed price	2022-08-17	72.9
Observed price	2022-09-06	69.5
Observed price	2022-09-18	67.8
Observed price	2022-09-30	71.2
Observed price	2022-10-04	71.7
Observed price	2022-10-16	75.4
Observed price	2022-11-09	77.1
Observed price	2022-11-17	74.4
Observed price	2022-11-25	77.7
Observed price	2022-12-07	71.8
Observed price	2022-12-19	73.3
Observed price	2023-01-04	76.2
Observed price	2023-01-16	81.1
Observed price	2023-01-28	74.9
Observed price	2023-02-01	73.8
Observed price	2023-02-21	79.1
Observed price	2023-02-25	81.4
Observed price	2023-03-13	78.3
Observed price	2023-03-21	79.0
Observed price	2023-04-10	86.3
Observed price	2023-04-14	87.7
Observed price	2023-05-04	83.6
Observed price	2023-05-20	87.7
Observed price	2023-05-28	82.5
Observed price	2023-06-01	82.0
Observed price	2023-06-17	85.5
Observed price	2023-06-25	81.6
Observed price	2023-07-11	78.5
Observed price	2023-07-23	81.6
Observed price	2023-08-04	79.4
Observed price	2023-08-20	81.5
Observed price	2023-08-28	82.8
Observed price	2023-09-21	83.5
Observed price	2023-09-25	80.7
Observed price	2023-10-15	80.2
Observed price	2023-10-19	75.2
Observed price	2023-10-23	71.9
Observed price	2023-11-12	66.2
Observed price	2023-11-20	68.1
Observed price	2023-12-06	74.2
Observed price	2023-12-14	74.7
Observed price	2023-12-30	79.3
Observed price	2024-01-03	80.7
Observed price	2024-01-23	84.8
Observed price	2024-01-27	85.7
Observed price	2024-02-16	94.9
Observed price	2024-02-20	95.1
Observed price	2024-03-07	110
Observed price	2024-03-15	104
Observed price	2024-04-04	116
Observed price	2024-04-08	114
Observed price	2024-04-28	125
Observed price	2024-05-10	120
Observed price	2024-05-22	129
Observed price	2024-05-30	128
Observed price	2024-06-15	138
Observed price	2024-06-19	138
Observed price	2024-07-09	144
Observed price	2024-07-17	140
Observed price	2024-07-29	157
Observed price	2024-08-06	149
Observed price	2024-08-26	162
Observed price	2024-09-03	164
Observed price	2024-09-07	161
Observed price	2024-10-01	163
Observed price	2024-10-13	172
Observed price	2024-10-21	172
Observed price	2024-11-06	180
Observed price	2024-11-18	165
Observed price	2024-11-30	186
Observed price	2024-12-12	180
Observed price	2024-12-24	192
Observed price	2025-01-09	197
Observed price	2025-01-17	183
Observed price	2025-01-21	183
Observed price	2025-02-10	191
Observed price	2025-02-14	180
Observed price	2025-03-06	192
Observed price	2025-03-18	182
Observed price	2025-03-30	164
Observed price	2025-04-03	161
Observed price	2025-04-11	134
Observed price	2025-04-27	153
Observed price	2025-05-01	165
Observed price	2025-05-29	157
Observed price	2025-06-10	163
Observed price	2025-06-18	158
Observed price	2025-06-26	170
Observed price	2025-07-08	170
Observed price	2025-07-28	183
Observed price	2025-08-05	184
Observed price	2025-08-21	196
Observed price	2025-08-25	199
Observed price	2025-09-10	209
Observed price	2025-09-18	203
Observed price	2025-10-08	257
Observed price	2025-10-12	260
Observed price	2025-11-01	221
Observed price	2025-11-05	219
Observed price	2025-11-25	237
Observed price	2025-12-07	246
Observed price	2025-12-19	237
Observed price	2025-12-31	236
Observed price	2026-01-08	253
Observed price	2026-01-28	253
Observed price	2026-02-05	268
Observed price	2026-02-17	284
Observed price	2026-03-01	253
Observed price	2026-03-13	250
Observed price	2026-03-17	258
Observed price	2026-03-29	255
Observed price	2026-04-10	275
Observed price	2026-04-22	243
Observed price	2026-05-04	229
Observed price	2026-05-16	236
Observed price	2026-06-05	260
Observed price	2026-06-13	269
Observed price	2026-06-21	248
Observed price	2026-07-03	260
Observed price	2026-07-15	236
Observed price	2026-07-27	246
Observed price	2026-08-16	214
Observed price	2026-08-24	220
Observed price	2026-09-09	205
Observed price	2026-09-17	209
Observed price	2026-09-22	214
Observed price	2026-09-25	214
Published advisor forecast	2026-09-18	208
Published advisor forecast	2026-12-18	216
Published advisor forecast	2027-03-18	229
Published advisor forecast	2027-06-18	236
Published advisor forecast	2027-09-18	227
Published advisor forecast	2027-12-18	238
Published advisor forecast	2028-03-18	252
Published advisor forecast	2028-06-18	260
Published advisor forecast	2028-09-18	265
Published advisor forecast	2028-12-18	276
Published advisor forecast	2029-03-18	290
Published advisor forecast	2029-06-18	281
Published advisor forecast	2029-09-18	289
Published advisor forecast	2029-12-18	301
Published advisor forecast	2030-03-18	313
Published advisor forecast	2030-06-18	319
Published advisor forecast	2030-09-18	310
Published advisor forecast	2030-12-18	319
Published advisor forecast	2031-03-18	332
Published advisor forecast	2031-06-18	338
Published advisor forecast	2031-09-18	342

2. Scenarios & Signals

Bull case

The bull case activates when rates fall and Washington stops being a variable. A 2027 Fed easing cycle lifts the discount applied to 2030s BIMZELX cash flows just as an MFN settlement removes the Section 232 duty entirely [12][14]. With tariff drag gone and peak guidance revised above €7bn on new indications, sustains above 42% and consensus EPS re-bases upward. Multiple expansion and earnings upgrades compound together, carrying the shares well past the €290 all-time high.

Bear case

The bear case begins with a single disclosure: BIMZELX net price per script falling faster than volumes rise. IRA Part D redesign and 340B expansion then convert a €7bn peak into a €5bn reality [8], while CIMZIA biosimilars arrive sooner than management assumes and BRIVIACT erosion accelerates in Europe. Earnings stall just as roughly $2.65bn of acquisition goodwill faces impairment testing, and an 18x multiple compresses toward 12x. The shares would revisit €140-150.

Current crowd narrative

The crowd treats UCB as a one-drug story that already worked. Sell-side targets cluster at €270-290 [18][19][20] against a €208 price, yet the shares sit 28% below February's €289.5 peak [15] — a classic anchoring to a superseded price rather than to cash flows. Consensus assumes €7bn BIMZELX peak is settled fact and treats US pricing policy as background noise.

Alpha-gap assessment

The crowd modestly underestimates these shares, but the case is narrower than screens suggest. The supplied dataset shows 11.4x trailing earnings and a 7% free-cash-flow yield; that is an artefact of summing four half-year periods for a semi-annual reporter. Reconstructed trailing is near €11.6, so the real multiple is roughly 18x. The genuine edge is different: a 28% de-rating driven by discount rates and tariff ambiguity, not by earnings — which have twice beaten upgraded guidance [1][4].

Convergence catalyst

The February 2027 full-year results are the test. Guidance arithmetic implies H2 2026 far below the €1.74bn booked in H1 [1][8]; if that proves conservatism rather than gross-to-net damage, a third upgrade forces re-rating. First sign: BIMZELX net price per script disclosed alongside volumes.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.2
Expected volatility regime: moderate
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Bimzelx Compounds Toward €7bn PEAK	BIMZELX doubled to €1.5bn in H1 2026 and management upgraded peak-sales guidance to at least €7bn [1][3]. The mechanism is indication stacking — psoriasis, PsA, axSpA and hidradenitis suppurativa — each adding volume onto a fixed commercial infrastructure, so incremental sales convert to EBITDA at high rates. With composition-of-matter protection running into the 2030s, this engine persists well beyond the forecast horizon.	Not available	+48.0%
Operating Leverage Finally Arrives	Adjusted EBITDA rose 68% to €1.74bn in H1 2026, lifting margin to 40.7% while revenue grew 22% [1][2]. UCB spent a decade building launch infrastructure ahead of revenue; that fixed cost base is now being amortised across a far larger sales line. Even with R&D guided near 25% of net sales, the gap between sales growth and cost growth should keep widening through 2028.	Not available	+22.0%
A Patent Cliff Nobody Faces Until 2033	Most European large-cap pharma trades under a visible 2028-2031 exclusivity wall. UCB's core growth assets face no material loss of exclusivity until 2033 on company disclosure [2], an unusually long runway that should command a scarcity premium once the legacy BRIVIACT and CIMZIA drag annualises out of the comparisons during 2027. Durability of cash flows, not growth rate alone, drives the re-rating.	Not available	+14.0%
CASH FLOW Funds THE NEXT Pipeline	FY2025 free cash flow of €1.88bn doubled year on year, financing roughly $2.65bn of 2026 upfronts for Candid Therapeutics and Neurona without straining a balance sheet carrying debt-to-equity of 0.21 [9][10][11]. Self-funded business development replenishes the post-2033 pipeline while modest buybacks and a rising dividend keep per-share economics intact. Discipline here, not scale for its own sake, protects shareholder returns.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Duration TAX FROM FIVE Percent Yields	The US 10-year closed at 4.998% on 18 September 2026 after a unanimous Fed hike to 3.75%-4.00%. UCB's value sits disproportionately in 2029-2037 BIMZELX cash flows, the most rate-sensitive part of any DCF. This explains the central anomaly: a 28% drawdown from the €289.5 February high [15] in the same year guidance was raised twice. Multiple compression, not operational failure.	Not available	-21.0%
Volume UP NET Price DOWN	Management conceded growth is increasingly volume-driven with net prices under pressure as US access broadens; a H2 2025 gross-to-net true-up equalled roughly 5% of BIMZELX revenue, and IRA Part D redesign plus a widening 340B effect drove CIMZIA's US price erosion [8]. This is structural American policy, not a negotiating cycle, so the wedge between prescriptions and realised revenue widens every year of the horizon.	Not available	-19.0%
Legacy Franchises Bleeding OUT	BRIVIACT net sales fell 13% to €327m in H1 2026 after February US generic entry, with European exclusivity lapsing in August 2026; CIMZIA, at €1.95bn the second-largest product, is already unprotected in both the US and EU [7][2]. Roughly a quarter of the revenue base is in structural decline, so headline growth understates how hard BIMZELX must work to carry the group.	Not available	-13.0%
Section 232 Tariff TOLL GATE	The April 2026 proclamation sets a 15% tariff on EU-origin patented pharmaceuticals, 20% for companies with approved onshoring plans from 29 September 2026, and 0% only for MFN-pricing signatories [12][13]. As a Belgian exporter into its largest market, UCB pays either a duty or a US price concession. No confirmed UCB agreement was found — that unresolved gap is worth several hundred basis points of group margin.	Not available	-11.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
PEAK Guidance Breaks Through €7bn	A further BIMZELX peak-sales upgrade — most plausibly at FY results in February 2028 or 2029 — triggered by label expansion into new immunology indications or convincing head-to-head data versus IL-23 incumbents. Because the consensus DCF anchors on the €7bn number [1], each €1bn of credible incremental peak sales flows almost entirely to EBITDA on an installed commercial base, justifying both higher forward EPS and a higher terminal multiple. It stays below 50% because IL-17/IL-23 competition and payer formulary design cap realistic share gains.	33.0%	+30.0%
ZERO Tariff MFN Settlement Signed	UCB joins the cohort of companies reaching a voluntary most-favoured-nation pricing agreement with Washington, securing the 0% Section 232 tier through January 2029 alongside a qualifying US onshoring plan [12][14]. Seventeen large pharma groups had already signed by May 2026. The effect is twofold: it removes a 15-20% duty on US-bound patented product and it converts an open-ended policy unknown into a dated, quantified contract — exactly the uncertainty discount the market currently applies. Likely window: late 2026 through 2027; below 50% because the required US net-price concessions may prove costlier than the duty.	30.0%	+16.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Rebate Mirage Behind THE €7bn	H1 2027 or FY2027 disclosure reveals that BIMZELX net price per script is falling fast enough that volume growth no longer converts into revenue growth — a repeat of the H2 2025 true-up worth roughly 5% of franchise sales, but structural [8]. Combined with an IL-17 class PBM exclusion, this would force a peak-sales downgrade, gutting the terminal value that supports an ~18x multiple. Probability is contained below 50% because access breadth is genuinely expanding and hidradenitis suppurativa carries limited competition.	30.0%	-30.0%
Billion Dollar BETS Written OFF	Cizutamig or NRTX-1001 fails in the clinic, or CIMZIA biosimilars arrive earlier than management's "no near-term entry" assumption, forcing impairment of the roughly $2.65bn of 2026 upfronts alongside a guidance cut [9][11][7]. With R&D already guided near 25% of net sales, a write-off would recast the acquisitions as expensive pipeline insurance and reopen questions about post-2033 durability. Most likely window: 2028-2030 data readouts. Below 50% because both assets are early and modelled conservatively by the sell side.	27.0%	-20.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_48afd3ad-d6e1-592f-ba85-0af549799c66__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (EUR)	Scenario rationale
1	December 18, 2026	+4.0%	216.42	Q3 trading update confirms BIMZELX momentum while the 29 September tariff tier decision resolves partially. Elevated European yields cap the rebound; modest recovery from an oversold base toward €215.
2	March 18, 2027	+6.0%	229.41	February FY2026 results are the pivotal test. H2 EBITDA reconciliation against guidance arithmetic likely reveals conservatism rather than gross-to-net damage, prompting a third upgrade and initial re-rating of depressed multiples.
3	June 18, 2027	+3.0%	236.29	BRIVIACT European erosion fully annualises and CIMZIA pricing pressure persists, but BIMZELX indication expansion sustains growth. Euro strength near 1.15 dilutes reported figures; gains remain incremental rather than decisive.
4	September 18, 2027	-4.0%	226.84	US net-price disclosure at H1 2027 results exposes widening gross-to-net wedge under IRA Part D redesign and 340B expansion. Sector-wide pricing anxiety and unresolved MFN status trigger a profit-taking correction.
5	December 18, 2027	+5.0%	238.18	Policy rates peak and begin easing as US inflation normalises below 3%, relieving the duration tax on long-dated BIMZELX cash flows. Discount-rate relief drives re-rating without operational change.
6	March 18, 2028	+6.0%	252.47	FY2027 results show revenue approaching €10bn with EBITDA margin sustained above 40%. Legacy drag now immaterial to growth arithmetic; the pure-growth profile earns a scarcity premium among European pharma.
7	June 18, 2028	+3.0%	260.05	Pipeline newsflow from Candid's cizutamig and early Neurona epilepsy data provides optionality without near-term earnings. Steady compounding as commercial infrastructure leverage continues to widen the cost-revenue gap.
8	September 18, 2028	+2.0%	265.25	Summer consolidation. Section 232 tariff arrangements settle into a predictable cost line, removing uncertainty premium but confirming a permanent margin toll on EU-origin patented product shipped to America.
9	December 18, 2028	+4.0%	275.86	Year-end positioning favours durable-growth pharma as the January 2029 expiry of MFN transition arrangements approaches. UCB's 2033 exclusivity runway differentiates it from peers facing 2029-2031 cliffs.
10	March 18, 2029	+5.0%	289.65	FY2028 results likely confirm BIMZELX approaching €5bn annualised, validating the upgraded peak trajectory. Free cash flow above €3bn supports accelerated buybacks, improving per-share economics materially.
11	June 18, 2029	-3.0%	280.96	Renewed US drug-pricing legislation ahead of the MFN expiry creates sector-wide derating. UCB's heavy American revenue concentration amplifies the headline risk despite unchanged underlying franchise performance.
12	September 18, 2029	+3.0%	289.39	Policy fears prove overstated as implementation details soften. Recovery driven by continued volume expansion in hidradenitis suppurativa and axial spondyloarthritis where competitive intensity remains comparatively low.
13	December 18, 2029	+4.0%	300.97	Pipeline maturation matters now. Positive Phase II readouts from acquired assets begin validating the $2.65bn deployed in 2026, extending the perceived duration of cash flows beyond 2033.
14	March 18, 2030	+4.0%	313.00	FY2029 results show revenue near €12bn with EBITDA margin stabilised in the low forties. Growth decelerates from explosive to solid; valuation support shifts from momentum to cash returns.
15	June 18, 2030	+2.0%	319.26	Maturing franchise dynamics. BIMZELX approaches its guided peak, so incremental upside depends on new indications rather than existing penetration. Modest appreciation tracking earnings growth alone.
16	September 18, 2030	-3.0%	309.69	Market begins discounting the 2033 exclusivity horizon three years ahead, as it habitually does. Terminal-value anxiety compresses the multiple despite continued operational delivery and strong cash conversion.
17	December 18, 2030	+3.0%	318.98	Management responds with pipeline visibility and possible further business development, reassuring investors on post-2033 durability. Partial recovery as capital-allocation credibility earned over the cycle is recognised.
18	March 18, 2031	+4.0%	331.74	FY2030 results confirm double-digit free-cash-flow yield on the original entry price. Dividend and buyback capacity expand materially, shifting the equity story from growth to cash-return compounding.
19	June 18, 2031	+2.0%	338.37	Steady state. Growth moderates to high single digits as the immunology portfolio matures; valuation converges toward European pharma sector norms rather than commanding a premium.
20	September 18, 2031	+1.0%	341.75	Horizon-end consolidation. The 2033 patent question dominates sentiment, offsetting solid execution. Total five-year appreciation of roughly 64% reflects earnings compounding partially offset by multiple normalisation.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase | UCBucb.com
[2]UCBJY H1 FY2026 earnings call — BigGo Financefinance.biggo.com
[3]Earnings call transcript: UCB lifts 2026 outlook as BIMZELX sales double in H1 2026 By Investing.cominvesting.com
[4]UCB H1 2026 slides: BIMZELX doubles sales, guidance upgraded By Investing.comza.investing.com
[5]Half Year 2026 Ucb SA Earnings Call Transcriptgurufocus.com
[6]UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum buildsfiercepharma.com
[7]UCB SA FY25 EBITDA jumps on Bimzelx surge; margin hit by one-offs By Investing.cominvesting.com
[8]UCB S.A. Earnings Call Highlights BIMZELX-Led Surge - The Globe and Mailtheglobeandmail.com
[9]UCB acquires Candid Therapeutics in $2.22bn deal — Financier Worldwidefinancierworldwide.com
[10]UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline | UCBucb.com
[11]UCB strikes $1.15B deal for cell therapy biotech Neuronafiercebiotech.com
[12]President Trump Announces Section 232 Tariffs on Pharmaceuticals and Active Pharmaceutical Ingredients | SmarTradethompsonhinesmartrade.com
[13]U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
[14]A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
[15]UCB Forecast — Price Target — Prediction for 2027 — TradingViewtradingview.com
[16]UCB stock edges lower as investors weigh Cimzia review and valuation gapad-hoc-news.de
[17]UCB stock gains as Baader Europe lifts price target on valuation opportunityad-hoc-news.de
[18]UCB Forecast — Price Target — Prediction for 2026 — TradingViewtradingview.com
[19]UCB SA (EBR:UCB) Stock Price & Overviewstockanalysis.com
[20]UCB.BR Stock Price, Quote & Chart | ChartMill.comchartmill.com
[21]UCB stock steadies as investors await next updatead-hoc-news.de
[22]UCB SA Share Price, Forecast & Financials (EBR:UCB) | Stockopediastockopedia.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Ray Dalio — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.